Can I survive long term taking Venetoclax?

Venetoclax (Venetoclax) is a novel orally bioavailable B-cell lymphoma-2 inhibitor that has demonstrated significant clinical activity in the treatment of chronic lymphocytic leukemia. Used alone or in combination with other targeted agents, venetoclax resulted in high rates of durable responses and undetectable measurable residual disease. Venaclat is unique in that it allows for fixed treatment duration of 12 months in the first-line setting and 24 months in the relapsed/refractory setting, with favorable impacts on compliance and pharmacoeconomics.

In clinical studies in patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), 75% of patients had objective responses, including 22% CR/CRi. Overall, 27% and 16% of patients acquired U-MRD in blood and bone marrow, respectively. The estimated median progression-free survival (PFS), DoR, and time to progression were 30.2, 38.4, and 36.9 months, respectively. Similar efficacy results were observed in the 400 mg/day monotherapy subgroup. For patients who achieved CR/CRi, the 3-year PFS estimate was 83%. In the landmark analysis, DoR was superior to patients achieving CR/CRi or U-MRD.

The original drug of Venacla is already on the market in China, and can be found in the Category B medical insurance directory. The specification is 100mg*14 tablets and the price per box may be around RMB 5,000. The Turkish version of Venaclaoriginal drug, specifications100mg*112 tablets, sold overseas, costs around RMB 10,000 per box (the price may fluctuate due to exchange rates), which is even more expensive. Cheaper generic drugs are also sold overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs. The price of a box of 100mg*120 tablets produced by a Bangladeshi pharmaceutical factory is around RMB 4,000 (prices may fluctuate due to exchange rates).